Rituximab: 13 open questions after 20years of clinical use

Pavanello, Francesca; Zucca, Emanuele; Ghielmini, Michele

doi:10.1016/j.ctrv.2016.11.015

Cited by 51 publications

(30 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study [45] reported that rituximab used with high-dose chemotherapy and stem cell transplantation emerged as an independent risk factor for solid tumour development. However, this finding was not confirmed by other studies [46,47], leaving the issue unresolved after 20 years of clinical use of rituximab [48]. However, it is crucial to stress the different contexts in which rituximab has been used historically, that include major hematological conditions and other malignancies.…”

Section: Discussionmentioning

confidence: 82%

Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome

Bonanni

Calatroni

D’Alessandro

et al. 2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome

Bonanni

Calatroni

D’Alessandro

et al. 2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Overviews of the safety profile of RTX in haematology reported infections (PML, spinal epidural abscess, viral hepatitis reactivation), haematologic disorders (acute thrombocytopenia and late onset neutropenia) and secondary malignancies . Importantly, in MS patients treated with RTX, cases with enterovirus encephalitis have been reported (pers.…”

Section: Discussionmentioning

confidence: 99%

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Infliximab: Infliximab is a recombinant humanized chimaeric antibody used for the treatment of ulcerative colitis, Crohn disease, rheumatoid arthritis, psoriatic arthritis/plaque psoriasis, and ankylosing spondylitis. It acts mainly by direct neutralization of soluble tumour necrosis factor-alpha, but it has also pro-apoptotic and anti-proliferative effects on lymphocytes[ 152 ].…”

Section: Alternative Treatmentsmentioning

confidence: 99%

Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments

Beretta‐Piccoli

Mieli‐Vergani

Vergani

2017

WJG

118

102

View full text Add to dashboard Cite

Autoimmune hepatitis is a rare chronic inflammatory liver disease, affecting all ages, characterised by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis at liver histology and good response to immunosuppressive treatment. If untreated, it has a poor prognosis. The aim of this review is to summarize the evidence for standard treatment and to provide a systematic review on alternative treatments for adults and children. Standard treatment is based on steroids and azathioprine, and leads to disease remission in 80%-90% of patients. Alternative first line treatment has been attempted with budesonide or cyclosporine, but their superiority compared to standard treatment remains to be demonstrated. Second-line treatments are needed for patients not responding or intolerant to standard treatment. No randomized controlled trials have been performed for second-line options. Mycophenolate mofetil is the most widely used second-line drug, and has good efficacy particularly for patients intolerant to azathioprine, but has the major disadvantage of being teratogenic. Only few and heterogeneous data on cyclosporine, tacrolimus, everolimus and sirolimus are available. More recently, experience with the anti-tumour necrosis factor-alpha infliximab and the anti-CD20 rituximab has been published, with ambivalent results; these agents may have severe side-effects and their use should be restricted to specialized centres. Clinical trials with new therapeutic options are ongoing.

show abstract

Rituximab: 13 open questions after 20years of clinical use

Cited by 51 publications

References 128 publications

Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome

Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments

Contact Info

Product

Resources

About